Advertisement
Citius Oncology, Inc.

CTOR News Today: Stay Updated with the Latest Citius Oncology, Inc. News in Real Time

Find CTOR news now at Meyka AI. Stay informed with the latest Citius Oncology, Inc. stocks updates, including price news, market analysis, and expert insights.

CTORNASDAQ
HealthcareDrug Manufacturers - General
$0.69
$0.03(4.58%)
U.S. Market opens in 16h 8m
Advertisement
NVIDIA Corp (NVDA -0.22% / -1.78% Pre-Market) Leads AI Chip Stocks Drop as AMD (-3.02%), Intel (-2.13%), and Micron (-1.41%) Decline 
📅 4 hours ago

NVIDIA Corp (NVDA -0.22% / -1.78% Pre-Market) Leads AI Chip Stocks Drop as AMD (-3.02%), Intel (-2.13%), and Micron (-1.41%) Decline 

NVIDIA shares fell 1.78% in pre-market trading on June 10, 2026, leading a broader decline across AI chip stocks. AMD dropped 3.02%, while Intel and Micron also traded lower as investors reacted to renewed concerns over inflation, interest rates, and technology valuations.  The selloff comes after a powerful AI-driven rally that pushed semiconductor stocks to…

Read more 12
SK Hynix Eyes U.S. Listing as Early as August Amid Strong AI Stock Demand 
📅 6 hours ago

SK Hynix Eyes U.S. Listing as Early as August Amid Strong AI Stock Demand 

SK Hynix is moving closer to a major milestone in its global growth strategy. Reports on June 10, 2026, revealed that the South Korean memory-chip giant is considering a U.S. stock market listing as early as August.  The timing comes as artificial intelligence continues to fuel strong demand for advanced semiconductor companies. With investors pouring…

Read more 12
Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug
📅 7 hours ago

Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug

Shares of Concord Biotech saw strong buying interest after a key global development. The stock rose around 5.9% in recent trading sessions after news of a US FDA approval related to its Tofacitinib-based arthritis drug. The trigger is important. The US Food and Drug Administration (FDA) approval opens doors to the world’s largest pharmaceutical market….

Read more 12
Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally
📅 1 day ago

Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally

Parabilis Medicines is aiming for a valuation of nearly $2.3 billion through an expanded U.S. initial public offering, highlighting renewed investor confidence in the biotechnology sector. The Cambridge, Massachusetts-based company increased the size of its offering as demand for biotech IPOs continues to improve following a challenging period for the industry. The company now plans…

Read more 12
United Natural Foods Stock Plunges 11% After $7.72B Revenue Miss and Weak FY2026 Outlook
📅 1 day ago

United Natural Foods Stock Plunges 11% After $7.72B Revenue Miss and Weak FY2026 Outlook

Revenue came in. The stock came down. United Natural Foods (NYSE: UNFI) reported fiscal Q3 2026 results before the market open on June 9, 2026, covering the 13 weeks ended May 2, 2026. Wall Street had set the bar at $7.80 billion in revenue and $0.77 EPS, based on consensus estimates from 10 analysts. The…

Read more 12
CoreWeave Inc Stock Gains 2.74% in Pre-Market as Founders Sell $2.3B Shares Post-IPO 
📅 1 day ago

CoreWeave Inc Stock Gains 2.74% in Pre-Market as Founders Sell $2.3B Shares Post-IPO 

CoreWeave Inc stock is in focus after a sharp pre-market move. The shares climbed about 2.74% even as news emerged that company founders sold nearly $2.3 billion worth of shares after the IPO. This kind of movement often creates confusion in the market. Normally, large insider selling can pressure a stock. But here, the price…

Read more 12
GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal 
📅 1 day ago

GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal 

GSK has made a major move in the global pharmaceutical industry. The company has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal. The offer price is $124 per share, which is about a 40% premium compared to the last closing price of Nuvalent. This is not a small deal. It is one…

Read more 12
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
📅 1 day ago

GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%

GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…

Read more 12
KOSPI Index Soars 8.18% to 8,096.93 as Institutional Buying Sparks Massive Market Rally
📅 1 day ago

KOSPI Index Soars 8.18% to 8,096.93 as Institutional Buying Sparks Massive Market Rally

South Korea’s stock market delivered a remarkable turnaround on June 9, 2026, as the KOSPI Index surged 8.18% to close at 8,096.93. The sharp rally came just a day after a major market selloff, highlighting the speed at which investor sentiment can shift. Strong institutional buying and renewed confidence in technology and semiconductor stocks fueled…

Read more 12

CTOR News FAQ